- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03592927
Acute Exposure to Simulated Hypoxia on Exercise Capacity
Acute Exposure to Hypoxia in Precapillary Pulmonary Hypertension: Physiological and Clinical Effects at Rest and During Exercise
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Low altitude baseline measurements will be performed in Zurich (460m asl) including Echocardiography, Right heart catheterization, six-minute walk test (6MWT), pulmonary function test, clinical assessment and blood gas Analysis.
Randomly assigned to the order of testing, the participants will be tested under simulated altitude (FiO2: 15.1% with the "AMC Altitrainer") and shamed altitude with the same device.
Towards the end of the exposure after approximately 1h, the participants will perform a constant loaded exercise test on an Ergometer with a calculated resistance of their 60% max. workload.
The patients will be encouraged to perform this test up to their physical exhaustion.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Zurich, Schweiz, 8091
- Respiratory Clinic, University Hospital of Zurich
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Informed consent
- PH diagnosed according to internation Guidelines: mean pulmonary artery presssure (mPAP) ≥ 25 mmHg along with a pulmonary artery wedge pressure (PAWP) ≤15 mmHg during right heart catheterization at the time of initial diagnosis
- PH class 1 (PAH) or 4 (CTEPH)
- Stable condition, on the same medication for > 4 weeks
- Patient live permanently at an altitude < 1000m asl.
Exclusion Criteria:
- Resting partial Oxygen pressure (PaO2) ≤7.3 kiloPascal (kPA) corresponding to the requirement of long-term oxygen therapy > 16hour daily (nocturnal oxygen therapy alone is allowed)
- Severe daytime hypercapnia (pCO2 > 6.5 kPa)
- Susceptibility to high altitude related diseases (AMS, High Altitude Pulmonary edema (HAPE), etc.) based on previous experienced discomfort at altitudes.
- Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the study participation
- Residence > 1000m above sea level
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with walking disability
- Women who are pregnant or breast feeding
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Order A
The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator ("Altitrainer", SMTEC), simulated altitude (FiO2: 15.1%), with a facemask.
|
Indånding af iltfri luft gennem en højdesimulator ("Altitrainer"), i ca. 1 time.
givet af en ansigtsmaske.
Inhalation of unmodified air through an altitude Simulator ("Altitrainer") for approximately 1 hour given by a facemask
|
|
Eksperimentel: Order B
The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator ("Altitrainer", SMTEC) with a facemask.
|
Indånding af iltfri luft gennem en højdesimulator ("Altitrainer"), i ca. 1 time.
givet af en ansigtsmaske.
Inhalation of unmodified air through an altitude Simulator ("Altitrainer") for approximately 1 hour given by a facemask
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Endurance time under hypoxia (FiO2: 15.1%)
Tidsramme: Towards the end of a one hour exposure
|
Constant loaded exercise test
|
Towards the end of a one hour exposure
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Schneider SR, Lichtblau M, Furian M, Mayer LC, Berlier C, Müller J, Saxer S, Schwarz EI, Bloch KE, Ulrich S. Cardiorespiratory Adaptation to Short-Term Exposure to Altitude vs. Normobaric Hypoxia in Patients with Pulmonary Hypertension. J Clin Med. 2022 May 14;11(10). pii: 2769. doi: 10.3390/jcm11102769.
- Schneider SR, Mayer LC, Lichtblau M, Berlier C, Schwarz EI, Saxer S, Furian M, Bloch KE, Ulrich S. Effect of Normobaric Hypoxia on Exercise Performance in Pulmonary Hypertension: Randomized Trial. Chest. 2021 Feb;159(2):757-771. doi: 10.1016/j.chest.2020.09.004. Epub 2020 Sep 9.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2018-00455_A1
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Pulmonal hypertension
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
BayerAfsluttet
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater
-
National Taiwan University Hospital Hsin-Chu BranchRekrutteringHypertension, essentiel | Hypertension, maskeretTaiwan
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Forenede Stater
-
University of Sao Paulo General HospitalRekrutteringPulmonal arteriel hypertension (PAH)Brasilien
-
University Hospital, BrestIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Frankrig
-
Shanghai Zhongshan HospitalIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)
-
Rutgers, The State University of New JerseyRekrutteringPulmonal arteriel hypertension | Pulmonal hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension af medfødt hjertesygdom | Pulmonal arteriel hypertension forbundet med skistosomiasis (lidelse) | Pulmonal arteriel og kronisk tromboembolisk pulmonal... og andre forholdForenede Stater